SLAMF7-directed Immunostimulatory Antibody [EPC]

4275 reported adverse events

Drugs of this class: ELOTUZUMAB

These side effects are most commonly reported by patients taking drugs of the SLAMF7-directed Immunostimulatory Antibody [EPC] class:

# Side effect Count
0 PLASMA CELL MYELOMA 352
1 PNEUMONIA 272
2 DEATH 265
3 MALIGNANT NEOPLASM PROGRESSION 224
4 PYREXIA 192
5 DIARRHOEA 191
6 FATIGUE 190
7 ANAEMIA 125
8 PLATELET COUNT DECREASED 122
9 NEUTROPENIA 121
See all common reactions for SLAMF7-directed Immunostimulatory Antibody [EPC]

Drugs of the SLAMF7-directed Immunostimulatory Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PARAINFLUENZAE VIRAL LARYNGOTRACHEOBRONCHITIS 2 0.6667
1 HUMAN METAPNEUMOVIRUS TEST 3 0.5000
2 ANTIVIRAL PROPHYLAXIS 1 0.1429
3 ANORECTAL HUMAN PAPILLOMA VIRUS INFECTION 3 0.1304
4 BLADDER TRANSITIONAL CELL CARCINOMA STAGE 0 2 0.0833
5 CONJUNCTIVOCHALASIS 1 0.0417
6 BLOOD IMMUNOGLOBULIN A ABNORMAL 1 0.0385
7 MENINGITIS STREPTOCOCCAL 4 0.0374
8 DEDIFFERENTIATED LIPOSARCOMA 1 0.0345
9 AEROMONAS INFECTION 4 0.0345
See all enriched reactions for SLAMF7-directed Immunostimulatory Antibody [EPC]